Liuya Wei

5.9k total citations · 4 hit papers
52 papers, 4.2k citations indexed

About

Liuya Wei is a scholar working on Molecular Biology, Hematology and Biomedical Engineering. According to data from OpenAlex, Liuya Wei has authored 52 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Molecular Biology, 14 papers in Hematology and 9 papers in Biomedical Engineering. Recurrent topics in Liuya Wei's work include Histone Deacetylase Inhibitors Research (10 papers), Nanoplatforms for cancer theranostics (8 papers) and Acute Myeloid Leukemia Research (8 papers). Liuya Wei is often cited by papers focused on Histone Deacetylase Inhibitors Research (10 papers), Nanoplatforms for cancer theranostics (8 papers) and Acute Myeloid Leukemia Research (8 papers). Liuya Wei collaborates with scholars based in China, United States and Israel. Liuya Wei's co-authors include Zhe‐Sheng Chen, Jing‐Quan Wang, Zhuo‐Xun Wu, Chuanxing Xiao, Dan Zhu, Xuan-Yu Chen, Jagadish Koya, Dongya Zhang, Kejun Hou and Jilin Li and has published in prestigious journals such as Chemical Communications, Chemical Engineering Journal and ACS Applied Materials & Interfaces.

In The Last Decade

Liuya Wei

49 papers receiving 4.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Microbiota in health and diseases

2022 1.7k citations Zhuo‐Xun Wu, Liuya Wei et al. profile →
Silver nanoparticles: synthesis, properties, and therapeutic applications

2014 757 citations Liuya Wei, Huizhong Xu et al. Drug Discovery Today profile →
Modulating ROS to overcome multidrug resistance in cancer

2018 545 citations Pranav Gupta, Liuya Wei et al. Drug Resistance Updates profile →
Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade

2022 152 citations Kun Pang, Zhenduo Shi et al. Drug Resistance Updates profile →

Peers

Countries citing papers authored by Liuya Wei

Since Specialization

Citations

This map shows the geographic impact of Liuya Wei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Liuya Wei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Liuya Wei more than expected).

Fields of papers citing papers by Liuya Wei

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Liuya Wei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Liuya Wei. The network helps show where Liuya Wei may publish in the future.

Co-authorship network of co-authors of Liuya Wei

This figure shows the co-authorship network connecting the top 25 collaborators of Liuya Wei. A scholar is included among the top collaborators of Liuya Wei based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Liuya Wei. Liuya Wei is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Composite Graphene for the Dimension- and Pore-Size-Mediated Stem Cell Differentiation to Bone Regenerative Medicine 2025 ·ACS Applied Materials & Interfaces ·Liuya Wei, Peilei Chen, (unknown), Gentao Li, (unknown), Yao Zhao, (unknown), Zhe‐Sheng Chen, Zhenbo Hu, (unknown), Baolong Zhou	3
2	Differentiation of Acute Leukemia Cells Including Cells with MLL-AF4 Rearrangements Induced by Jiyuan Oridonin A 2024 ·Recent Patents on Anti-Cancer Drug Discovery ·Xueming Li, (unknown), Yu Ke, Hong‐Min Liu, Zhenbo Hu, Liuya Wei	0
3	Glutathione‐Sensitive Photosensitizer–Drug Conjugates Target the Mitochondria to Overcome Multi‐Drug Resistance in Cancer 2024 ·Advanced Science ·Weiguo Song, (unknown), Ying Wang, Shuzhen Chen, Wenda Zhong, Qian Wang, (unknown), Guangzhao Xu, Meng Chen, Ying Liang, Zhe‐Sheng Chen, Shuhua Cao, Liuya Wei, (unknown)	17
4	Crown ether-based porous organic polymer encapsulated Ag2[Fe(CN)5NO] composite towards ultra-low dose efficient sterilization and wound healing application 2023 ·Materials Today Chemistry ·(unknown), (unknown), (unknown), Peilei Chen, Peng Sun, Zhe‐Sheng Chen, Liuya Wei, Baolong Zhou	11
5	I13 overrides resistance mediated by the T315I mutation in chronic myeloid leukemia by direct BCR-ABL inhibition 2023 ·Frontiers in Pharmacology ·(unknown), Lei Zhang, Yun Xu, Xiangyu Ma, Peilei Chen, Zhe‐Sheng Chen, Liuya Wei	5
6	Composite porphyrin-based conjugated microporous polymer/graphene oxide capable of photo-triggered combinational antibacterial therapy and wound healing 2023 ·Biomaterials Advances ·Peilei Chen, (unknown), Xiaohui Xia, Zifan Zhang, (unknown), Liuya Wei, Baolong Zhou	18
7	Dostarlimab in the treatment of mismatch repair deficient recurrent or advanced endometrial cancer 2023 ·PubMed ·(unknown), Harsh Patel, Shuzhen Chen, (unknown), Liuya Wei, Zhe‐Sheng Chen	2
8	Silver-dendrimer nanocomposite as emerging therapeutics in anti-bacteria and beyond 2023 ·Drug Resistance Updates ·Xiaoling Fu, (unknown), Liuya Wei, Zhe‐Sheng Chen, Mohammed A. S. Abourehab, Prashant Kesharwani, (unknown)	26
9	Endoplasmic reticulum and mitochondrial double-targeted NIR photosensitizer synergistically promote tumor cell death 2023 ·Materials & Design ·(unknown), Fahui Li, Shuzhen Chen, (unknown), (unknown), Wen Sun, Liuya Wei, Guangzhao Xu, Weiguo Song, Wenda Zhong	9
10	Histone Deacetylase Inhibitor I3 Induces the Differentiation of Acute Myeloid Leukemia Cells with t (8; 21) or MLL Gene Translocation and Leukemic Stem-Like Cells 2022 ·Journal of Oncology ·Mengjie Zhao, (unknown), Jiangyun Wang, Yong Liu, Yao Zhao, Haihua Wang, Lei Zhang, Zhe‐Sheng Chen, Zhenbo Hu, Liuya Wei	5
11	Simultaneous self-supply of H₂O₂ and GSH-depleted intracellular oxidative stress for enhanced photodynamic/photothermal/chemodynamic therapy 2022 ·Chemical Communications ·Qian Wang, Fahui Li, (unknown), Ying Wang, (unknown), (unknown), Liuya Wei, Shuhua Cao, Weiguo Song	20
12	Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade breakdown → 2022 ·Drug Resistance Updates ·Kun Pang, Zhenduo Shi, Liuya Wei, Dong Yang, (unknown), Wei Wang, Guangyue Wang, (unknown), Jiajun Dong, (unknown), Peng Zhang, Hao Lin, Hao Xu, Deng Pan, Zhe‐Sheng Chen, Conghui Han	152
13	Discovery of 2-(4-Acrylamidophenyl)-Quinoline-4-Carboxylic Acid Derivatives as Potent SIRT3 Inhibitors 2022 ·Frontiers in Chemistry ·(unknown), Xueming Li, Wenli Fan, (unknown), Lin Zhang, Hongyu Qin, Liuya Wei, Lei Zhang	14
14	Asparaginase Erwinia chrysanthemi for acute lymphoblastic leukemia and lymphoblastic lymphoma 2022 ·Drugs of today ·(unknown), Xiangyu Ma, Zifan Zhang, (unknown), Charles R. Ashby, Liuya Wei, Zhe‐Sheng Chen	4
15	Jiyuan Oridonin A Overcomes Differentiation Blockade in Acute Myeloid Leukemia Cells With MLL Rearrangements via Multiple Signaling Pathways 2021 ·Frontiers in Oncology ·Meihua Qu, (unknown), Min Zhao, (unknown), Mengjie Zhao, Yao Zhao, Haihua Wang, Yu Ke, Ying Liu, Hong‐Min Liu, Liuya Wei, Zhenbo Hu	11
16	A Small Molecule Inhibitor, OGP46, Is Effective against Imatinib-Resistant BCR-ABL Mutations via the BCR-ABL/JAK-STAT Pathway 2020 ·Molecular Therapy — Oncolytics ·Liuya Wei, Yang Yang, Pranav Gupta, Aihong Wang, Min Zhao, Yao Zhao, Meihua Qu, Yu Ke, Ying Liu, Hong‐Min Liu, Xin Xu, Yanli Sun, Zhe‐Sheng Chen, Zhenbo Hu	11
17	Overexpression of ABCG2 confers resistance to pevonedistat, an NAE inhibitor 2020 ·Experimental Cell Research ·Liuya Wei, Zhuo‐Xun Wu, Yang� Yang, Min Zhao, Xiangyu Ma, (unknown), Dong‐Hua Yang, Zhe‐Sheng Chen, Yingfang Fan	18
18	A Stable Pep2-proapoptotic Peptide Inducing Apoptosis of Acute Myeloid Leukemia Cells by Down-Regulating EZH2 2019 ·Cellular and Molecular Bioengineering ·Yanli Sun, Jiaqiu Li, Yanhua Sun, Ronglan Zhao, Lujuan Wang, Wei Song, (unknown), Jialing Wang, Liuya Wei, Yao Zhao, Yang Song, Zhenbo Hu	3
19	PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia 2016 ·Cancer Letters ·Pranav Gupta, Rishil J. Kathawala, Liuya Wei, Fang Wang, (unknown), Brian Druker, Liwu Fu, Zhe‐Sheng Chen	23
20	Silver nanoparticles: synthesis, properties, and therapeutic applications breakdown → 2014 ·Drug Discovery Today ·Liuya Wei, (unknown), Huizhong Xu, Atish Patel, Zhe‐Sheng Chen, Guofang Chen	757

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact